APPENDIX

OnlineTable 1. Randomized controlled trials included in the meta-analysis

Study / Stent comparators
1 / BASKET PROVE(1), 2010 / CoCr-EES vs SES vs BMS
2 / CIBELES(2), 2013 / CoCr-EES vs SES
3 / COMFORTABLE AMI(3), 2012 / BP-BES vs BMS
4 / COMPARE(4), 2010 / CoCr-EES vs PES
5 / COMPARE II(5), 2013 / CoCr-EES vs BP-BES
6 / DEBATER(6), 2012 / SES vs BMS
7 / DES-DIABETES(7), 2008 / SES vs PES
8 / DESSERT(8), 2008 / SES vs BMS
9 / DIABEDES(9), 2009 / SES vs PES
10 / DIABETES(10), 2005 / SES vs BMS
11 / Diaz de la Llera(11), 2007 / SES vs BMS
12 / ENDEAVOR II(12), 2006 / PC-ZES vs BMS
13 / ENDEAVOR III(13), 2006 / PC-ZES vs SES
14 / ENDEAVOR IV(14), 2010 / PES vs PC-ZES
15 / Erglis(15), 2007 / PES vs BMS
16 / ESSENCE DIABETES(16), 2010 / CoCr-EES vs SES
17 / EXAMINATION(17), 2012 / CoCr-EES vs BMS
18 / EXCELLENT(18), 2010 / CoCr-EES vs SES
19 / GISSOC-II-GISE(19), 2010 / BMS vs SES
20 / GRACIA-3(20), 2010 / PES vs BMS
21 / HAAMU(21), 2006 / PES vs BMS
22 / Herdeg(22), 2009 / BMS vs Pacl+BMS vs PES
23 / HORIZONS-AMI(23), 2009 / PES vs BMS
24 / HOST-ASSURE(24), 2013 / PtCr-EES vs Re-ZES
25 / ISAR DESIRE(25), 2010 / PES vs SES
26 / ISAR DIABETES(26), 2005 / PES vs SES
27 / ISAR LEFT MAIN(27), 2009 / PES vs SES
28 / ISAR SMART III(28), 2006 / PES vs SES
29 / ISAR TEST IV(29), 2009 / CoCr-EES vs SES
30 / Juwana(30), 2009 / PES vs SES
31 / Kamoi(31), 2011 / PES vs SES
32 / Kim(32), 2008 / PES vs SES
33 / KOMER(33), 2011 / PES vs SES vs PC-ZES
34 / LEADERS(34), 2008 / BP-BES vs SES
35 / LONG-DES II(35), 2006 / SES vs PES
36 / LONG-DES III(36), 2011 / CoCr-EES vs SES
37 / MISSION(37), 2008 / BMS vs SES
38 / MULTISTRATEGY(38), 2008 / BMS vs SES
39 / NAPLES(39), 2011 / PES vs SES vs PC-ZES
40 / NEXT(40), 2013 / BP-BES vs EES
41 / NOBORI I phase I(41), 2007 / BP-BES vs PES
42 / NOBORI I phase II(42), 2009 / BP-BES vs PES
43 / NOBORI JAPAN(43), 2011 / BP-BES vs SES
44 / Ortolani(44), 2007 / SES vs BMS
45 / Pache(45), 2005 / BMS vs SES
46 / Pan(46), 2007 / SES vs PES
47 / Pasceri(47), 2003 / BMS vs SES
48 / PASEO(48), 2009 / PES vs SES vs BMS
49 / PASSION(49), 2008 / BMS vs PES
50 / Petronio(50), 2007 / SES vs PES
51 / PLATINUM(51), 2011 / PtCr-EES vs CoCr-EES
52 / PRISON II(52), 2006 / SES vs BMS
53 / PROSIT(53), 2008 / PES vs SES
54 / PROTECT(54), 2012 / PC-ZES vs SES
55 / RAVEL(55), 2002 / SES vs BMS
56 / REALITY(56), 2006 / PES vs SES
57 / RESET(57), 2011 / CoCr-EES vs SES
58 / RESOLUTE(58), 2010 / CoCr-EES vs Re-ZES
59 / SCANDSTENT(59), 2006 / SES vs BMS
60 / SCORPIUS(60), 2007 / SES vs BMS
61 / SEA-SIDE(61), 2011 / CoCr-EES vs SES
62 / SELECTION(62), 2007 / BMS vs PES
63 / SESAMI(63), 2007 / BMS vs SES
64 / SES-SMART(64), 2004 / SES vs BMS
65 / SIRIUS(65), 2003 / SES vs BMS
66 / E-SIRIUS(66), 2003 / SES vs BMS
67 / C-SIRIUS(67), 2004 / SES vs BMS
68 / SIRTAX LATE(68), 2011 / PES vs SES
69 / SORT OUT II(69), 2008 / PES vs SES
70 / SORT OUT III(70), 2010 / PC-ZES vs SES
71 / SORT OUT IV(71), 2010 / CoCr-EES vs SES
72 / SORT OUT V(72), 2012 / BP-BES vs SES
73 / SOS(73), 2009 / BMS vs PES
74 / SPIRIT II(74), 2006 / CoCr-EES vs SES
75 / SPIRIT III(75), 2008 / CoCr-EES vs PES
76 / SPIRIT IV(76), 2010 / CoCr-EES vs PES
77 / SPIRIT V DIABETIC(77), 2010 / CoCr-EES vs PES
78 / STRATEGY(78), 2007 / BMS vs SES
79 / TAXi(79), 2004 / PES vs SES
80 / TAXUS I(80), 2003 / BMS vs PES
81 / TAXUS II(81), 2003 / BMS vs PES
82 / TAXUS IV(82), 2004 / BMS vs PES
83 / TAXUS V(83), 2005 / BMS vs PES
84 / TAXUS VI(84), 2005 / BMS vs SES
85 / TWENTE (85), 2011 / CoCr-EES vs Re-ZES
86 / TYPHOON(86), 2006 / BMS vs SES
87 / XAMI(87), 2012 / CoCr-EES vs SES
88 / ZEST(88), 2010 / PES vs SES vs PC-ZES
89 / ZEST-AMI(89) 2009 / PES vs SES vs PC-ZES

References

1.Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010;363:2310-9.

2.Moreno R, Garcia E, Teles R, et al. Randomized Comparison of Sirolimus-Eluting and Everolimus-Eluting Coronary Stents in the Treatment of Total Coronary Occlusions: Results From the Chronic Coronary Occlusion Treated by Everolimus-eluting Stent Randomized Trial. Circ Cardiovasc Interv 2013;6:21-8.

3.Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87.

4.Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.

5.Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60.

6.Wijnbergen I, Helmes H, Tijssen J, et al. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. JACC Cardiovasc Interv 2012;5:313-22.

7.Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008;52:727-33.

8.Maresta A, Varani E, Balducelli M, et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 2008;101:1560-6.

9.Maeng M, Jensen LO, Galloe AM, et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 2009;103:345-9.

10.Jimenez-Quevedo P, Sabate M, Angiolillo DJ, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006;47:2172-9.

11.Diaz de la Llera LS, Ballesteros S, Nevado J, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007;154:164 e1-6.

12.Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.

13.Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7.

14.Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010;55:543-54.

15.Erglis A, Narbute I, Kumsars I, et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007;50:491-7.

16.Kim WJ, Lee SW, Park SW, et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation 2011;124:886-92.

17.Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90.

18.Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011;58:1844-54.

19.Rubartelli P, Petronio AS, Guiducci V, et al. Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. Eur Heart J 2010;31:2014-20.

20.Sanchez PL, Gimeno F, Ancillo P, et al. Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circ Cardiovasc Interv 2010;3:297-307.

21.Tierala I, Nikus KC, Sclarovsky S, Syvanne M, Eskola M. Predicting the culprit artery in acute ST-elevation myocardial infarction and introducing a new algorithm to predict infarct-related artery in inferior ST-elevation myocardial infarction: correlation with coronary anatomy in the HAAMU Trial. J Electrocardiol 2009;42:120-7.

22.Herdeg C, Gohring-Frischholz K, Haase KK, et al. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Interv 2009;2:294-301.

23.Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59.

24.Kim H-S, Park K-W, Kang S-H, et al. Randomized Comparison of PtCr-EES vs CoCr-ZES in All-Comers Receiving PCI : The HOST-ASSURE Randomized Trial. Presented at the American College of Cardiology, S. Francisco 2013.

25.Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010;55:2710-6.

26.Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.

27.Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009;53:1760-8.

28.Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-6.

29.Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009;30:2441-9.

30.Juwana YB, Suryapranata H, Ottervanger JP, et al. Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 2009;104:205-9.

31.Kamoi D, Ishii H, Takahashi H, et al. Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients. Int J Cardiol 2011; 165:533-6.

32.Kim MH, Hong SJ, Cha KS, et al. Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv Cardiol 2008;21:225-31.

33.Kang WC, Ahn T, Lee K, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 2011;7:936-43.

34.Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73.

35.Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006;114:2148-53.

36.Park DW, Kim YH, Song HG, et al. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv 2011;4:1096-103.

37.van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008;51:618-26.

38.Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008;299:1788-99.

39.Briguori C, Airoldi F, Visconti G, et al. Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. Circ Cardiovasc Interv 2011;4:121-9.

40.Natsuaki M, Kozuma K, Morimoto T, et al. One-Year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer. Presented at the American College of Cardiology, S. Francisco 2013.

41.Chevalier B, Serruys PW, Silber S, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007;2:426-34.

42.Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. Circ Cardiovasc Interv 2009;2:188-95.

43.Kadota K, Muramatsu T, Iwabuchi M, et al. Randomized comparison of the Nobori Biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv 2012;80:789-96.

44.Ortolani P, Marzocchi A, Marrozzini C, et al. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv 2007;69:790-8.

45.Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8.

46.Pan M, Suarez de Lezo J, Medina A, et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J 2007;153:15 e1-7.

47.Pasceri V GA, Pristipino C, et al. A randomized trial of arapamycin-eluting stent in acute myocardial infarction: preliminary results. TCT 2003. Am J Cardiol 2003. 2003;92 (Suppl 6A).

48.Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv 2009;2:515-23.

49.Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13.

50.Petronio AS, De Carlo M, Branchitta G, et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol 2007;49:539-46.

51.Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011;57:1700-8.

52.Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006;114:921-8.

53.Lee JH, Kim HS, Lee SW, et al. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv 2008;72:25-32.

54.Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1396-405.

55.Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.

56.Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904.

57.Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation 2012;126:1225-36.

58.Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.

59.Kelbaek H, Thuesen L, Helqvist S, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006;47:449-55.

60.Baumgart D, Klauss V, Baer F, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007;50:1627-34.

61.Burzotta F, Trani C, Todaro D, et al. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv 2011;4:327-35.

62.Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007;20:282-91.

63.Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007;49:1924-30.

64.Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34.

65.Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.

66.Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.

67.Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.

68.Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011;123:2819-28.

69.Galloe AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008;299:409-16.

70.Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010;375:1090-9.

71.Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012;125:1246-55.

72.Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013;381:661-9.

73.Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009;53:919-28.

74.Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention 2006;2:286-94.

75.Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13.

76.Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.

77.Grube E, Chevalier B, Guagliumi G, et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J 2012;163:867-875 e1.

78.Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007;50:138-45.